On June 16, 2023, SQI Diagnostics (SQI), a leader in the science of lung testing, announced that it planned to voluntarily file for bankruptcy.  Upon the legal action being filed the shares of the publicly traded SQI Diagnostics that are held by more than 1,000 shareholders would have become worthless.   Michael Markowski, an analyst who had recommended the shares of SQI interceded to prevent the bankruptcy from being filed.  SQI Diagnostics’ stock symbols:

Canada: SQD.V

US: SQIDF

In his March 30, 2023 ShinyPennyStocks.com “Timing is FINALLY Right for SQI Diagnostics’ Shares” research report Michael Markowski recommended SQIDF shares at a limit price of $0.05.  His rationale for the recommendation was because:

• SQI had submitted several lung testing products to the US. FDA and Canada’s Health Canada regulatory bodies. Regulatory approval for some of the products was granted in 2022.  SQI anticipates that a majority of all of the testing products including its TorDX donor lung testing product will be approved by regulators by the end of 2024.
• SQI’s share price was 90% below its all-time high.

SQI’s proprietary products, upon approval, could potentially value SQI for a billion, equivalent to a share price of $2.00 or above.  Because SQI had a diversified portfolio of change-the-world respiratory products and had other intangibles Mr. Markowski stated “SQI has the best risk reward ratio of any stock that I have ever recommended throughout my 46-year career” in his March 2023 research report.    

After SQI made its bankruptcy announcement, Michael questioned as to why the company’s Board of Directors (BOD) would make such a rash decision.  He contacted the secured creditor, which had sent the foreclosure notice to SQI.  The notice had prompted SQI’s decision to voluntarily seek bankruptcy protection. 

Michael Markowski was surprised to learn that the foreclosing creditor was willing to convert the debt owed by SQI into an equity stake in the company.  Since the creditor was not the catalyst for SQI’s decision to file for bankruptcy he analyzed the public company’s Financial Statements and disclosures.  Mr. Markowski discovered that the majority of SQI’s Board of Directors (BOD) were also secured creditors.  This meant, that in the event of a bankruptcy, the members of the BOD who were secured creditors would continue to have a stake in SQI’s products and intellectual property. 

Armed with this information, Mr. Markowski began his battle to STOP SQI from filing for bankruptcy.  Michael produced a 6/19/23 memo in support of why the bankruptcy should not be filed.  He informed the members of SQI’s BOD that they were self-serving and not acting in the best interests of the company’s minority shareholders.  He cited the conflicts that necessitated a restructuring of SQI’s BOD.  Michael demanded that the conflicted secured lender/directors resign and that his three BOD nominees be elected to SQI’s BOD:

• Dr.David Weill, former Director of the Center for Advanced Lung Disease and Lung and Heart-Lung Transplant Program at Stanford University Medical Center
• David Markowski, former CFO of a publicly traded company and registered investment advisor
• Deborah Markowski, registered investment advisor

In a 6/22/23 follow-up email to the directors Michael Markowski said:

“The bottom line is that SQI Diagnostics will be the cherry on top of the cake when my career ends one way or another.  

1. Biggest stock ever
2.  I will become the most well-known shareholder advocate ever.  The “Ralph Nader” for investors.  

If SQI files for bankruptcy, I will have no choice but to lead the effort for the behalf of all of the shareholders to vigorously pursuit all of the existing board members.  This will enable me to protect and to increase the value of my brand.  Articles have been written about me by every major financial publication throughout my career and Fortune Magazine named me as one of their top 50 investors.    

I guarantee you that lawsuits will be filed against each of the Board members.  Since SQI Diagnostics Inc. has done nothing wrong there will be no need for a class action lawsuit.   

To fund the lawsuits articles will be published about the despicable things that the SQI Board members did and how they did nothing to protect SQI’s common shareholders. My award-winning reporter contact at the Wall Street Journal will love this story.  SQI will become the poster child for why Directors should not be self-serving”.   

Video below is a clip from Michael Markowski’s weekly “Markowski on the Market” Saturday 6/24/23 session.  It’s about the ultimatum that he gave to the SQI Directors. 

On 6/23/23 SQI’s Board of directors relented.  The bankruptcy for SQI was not filed and SQI agreed to restructure its Board of directors.  Mr. Markowski’s director nominees would be elected and would constitute the majority for the SQI Board of Directors.  At July 7, 2023, the details to incorporate the changes were in the process of being worked out.  

Video below is a clip from Michael Markowski’s weekly “Markowski on the Market” Saturday 7/01/23 session.  It’s about the potential price target for SQIDF shares after the SQI-will-not-seek to-file-for-bankruptcy announcement is made.

Video below is a 7/8/23 update on SQI Diagnostics during “Markowski on the Market” weekly Saturday 11:00AM session. 

For updates on SQI Diagnostics subscribe to ShinyPennyStocks.com.  The site offers a free 90- day subscription. 

Investview shares (ticker: INVU) traded to as low as $0.017 and have been trading at prices below $0.02 since the company reported its results for the year ended December 31, 2022. Based on my analysis of the financials Investview shares should be aggressively purchased at a buy limit price of $0.03. The share price should easily double from the recent low and could potentially reach $0.10 should Bitcoin continue to trend higher. The price targets assume that the company is not acquired. However, the probability of this happening is very high. Video: “Why Probability High for Investview to be Acquired” is at bottom of page.

Please note. I have predicted the most significant decline for the S&P 500 from its January 2022 all-time high since the index’s 85% decline from 1929 to 1932.  I also have predicted that the US by end of 2023 will enter into its first Great Depression since 1929-1938.  For predictions and articles in support of predictions view “Videos & Articles Supporting Markowski’s S&P to Crash & to Cause next Great Depression Predictions”.

All of my friends, family and followers are being advised to adopt and deploy the defensive “Return OF Capital” defensive strategy.  For more about the strategy which includes a portfolio’s allocation to low price shares an small companies increasing view my “Return OF Capital” vs. “Return ON Capital” video. 

INVU shares have been driven down to going-out-of-business prices for two reasons:

• • Company reported a loss of $8.6 million for year ended 12/31/2022. See March 31, 2022 press release.  
  • Investors perceive company to be a crypto mining play and prices for crypto currencies have taken a beating over last 12 months.

The “headline earnings loss” has provided opportunities for both an immediate short-term gain and also a 10X long term gain.  Investview for its latest 12 months ended December 31, 2022 had:

• • generated $9.4 million of positive operating cash flow
  • current assets of $26 million including $20 million of cash
  • an accumulated deficit or tax loss carryforward of $89.5 million

Investview at a share price of $0.037 or below would be an ideal acquisition candidate based on the above three items alone. 

Investview’s share price has the potential to get to a dime or higher by year end.  Its because the company’s wholly owned iGenius LLC subsidiary which accounted for 80%  of the company’s revenue weathered the 12-month crypto storm.  The storm began in November of 2021 at Bitcoin’s peak and ended in November 2022 at Bitcoin’s bottom. 

The chart below depicts that Bitcoin steadily declined from its November 2021 all-time high until it bottomed at $15,599.05, on November 21, 2022 and the digital coin’s bottoming process began.  The chart illustrates the narrow trading range for a Bitcoin before it rose to above $18,000 on January 12, 2023.

For the 12 months ended 2022, which covered most of the crypto 2021-2022 winter, iGenius’  subscription revenue declined by 1.2% from $48.86 million to $48.26 million.  The minimal revenue decline is significant.  It speaks volumes for the stickiness of and the value that the company’s iGenius subsidiary provides to crypto traders, etc.  Its especially since a significant number of iGenius’ subscribers trade crypto currencies.

iGenius offers multiple services and products, both domestically and internationally, through a direct selling network, also known as multi-level marketing.  Their independent distributors offer products and services through a subscription-based revenue model to a large base of customers or members.  These services and products consist of the offering of research, education, and investment tools including artificial intelligence bots that enable members to auto trade.   All of the products and services are designed to assist the self-directed investor in successfully navigating the financial markets, including equities, options, FOREX, ETFs, binary options, and cryptocurrencies.   There are multiple tiers of membership at varying upfront and monthly subscription costs, which provide members with the ability to select from a range of membership packages to meet their product and service needs and price point.

The members continued to pay their subscription fees through the crypto winter because the iGenius offerings include a guarantee of satisfaction to each new subscriber or member.  During the designated trial period, which is 10 days from initial purchase for domestic customers and 14 days from initial purchase for international customers, should the member for any reason not be satisfied the member may request a full refund of their subscription.  iGenius’ full satisfaction guarantee has created a culture that reduces subscriber turnover.  The result is the company’s subsidiary has a large and low turnover base of passionate members.  The photo below was taken in 2021 at an event for members that was held by iGenius in Egypt in 2021.

The Zoom in below is for the above photo.  It depicts that the audience consists mostly of young men and women.  All of the world’s crypto, stock brokerages and financial services providers would die to have a customer acquisition model that could attract a global demographic.

The large and sticky subscriber base is yet another reason why Investview has a high probability to be acquired.  Think or Swim (Investools), which ranks as my best ever buy and hold recommendation with a return of 150.9 times investment, had a model that was almost identical to iGenius.  The only difference was that Investools utilized a brick-and-mortar seminar strategy to educate its students.  The student/subscribers were easily converted to brokerage clients after the company acquired online broker Think or Swim.  Investview’s digital model is much more robust and scalable when compared Investools.   

For Investview shares to get to back above the April 2021 $0.79 high the company will have to acquire an online crypto or a securities brokerage firm.   The acquisition would enable it to fully leverage iGenius’ subscriber base.  All have online brokerage accounts to trade stocks and crypto currencies.

The wild card for Investview, which could potentially increase the share price to well above 10₵, very quickly is its Bitcoin mining operation.  The mining division accounted for only 19.4% of 2022 revenue.  This compared to mining accounting for 32.2% of revenue in calendar 2021. 

Investview’s mining revenue and mining profits are highly correlated with the price direction for Bitcoin.   The chart below depicts the share price patterns for Investiew and the three other publicly traded bitcoin miners.  It depicts that Investview’s share price has a history for lagging the upside price moves for the shares of the three other miners.  This is not surprising since INVU shares trade for less than a $1.00 and there are no institutions which hold the shares.

Unless Investview’s shares can increase to and maintain a price of $0.04 or above the probability is high that the company will be acquired. My recommendation is for shares to be aggressively purchased at limit price at or below $0.03 per share. Investview will continue to be monitored closely. The limit price for the shares will likely be raised in the future and published on ShinyPennySTocks.com when warranted.

The timing is excellent to buy and hold the shares of SQI Diagnostics (SQI) for a 10X to 100X gain.  The share price at its all-time low in early March 2023 was 99.25% below its 2011 all-time high.  SQI shares trade in Canada (symbol:SQD) and also in the U.S (symbol: SQIDF).

Please note.  For why SQI Diagnostics has the best risk reward metrics of any stock that I have recommended since 1978 see my conclusion at bottom of the page.  Also view recent video Money TV interviews of myself about SQI and Andrew Morris, CEO of SQI at bottom of page.

Based on my 46 years of experience in the markets the best time to buy an early-stage medical biotech, medical device or testing company that has Intellectual Property (IP) which requires government approval, is after the company’s IP submission gains government approval.  Below is the typical IPO-to-government-approval share price depreciation/appreciation cycle for medical companies that have proprietary IP:

• • Company with IP raises money via public offering.
  • Clinical trials and waiting game for regulatory approval begins
  • Share price subsequently climbs to all-time high in less than a few years.
  • Share price trends lower and to all-time low since approval always requires more time than projected.
  • Government approval obtained at or near all-time low.
  • Share price climbs back to all-time high.

Sarepta Therapeutics, Inc. (SRPT) is a good example.  The chart below depicts that SRPT’s share price followed the cycle.  The high share price on the 06/04/1997 date of its IPO was $40.50.  After reaching an all-time high of $162.00 on 02/09/2000 SRPT declined to an all-time low of $2.70 on 11/21/2008.  On 09/19/2016, when Sarepta’s first drug was approved by the FDA, a share could have been purchased for as low as $28.10.  Since then, a SRPT share has traded as high as $181.83.  The share price eclipsed its 2000 all-time high on 10/01/2018.  For the approximate 24 months from the approval to the new high the share price multiplied by five times. 

The chart below depicts that SQIDF’s share price has also been following the cycle.  The share price on 8/12/09 its first day of trading closed at $1.78.  The shares reached their all-time high of $3.60 on 06/27/2011.  The share priced reached their all-time low of $0.027 on 03/02/2023.

SQI Diagnostics is a leader in the science of lung health. They develop and manufacture 15-minute point of care tests for respiratory health and precision medicine.   SQI’s tests simplify and improve respiratory distress testing, donor organ transplant informatics and post transplant patient monitoring.

In short, SQI helps doctors identify risks to their patient’s  lung health so they can make good choices and deliver the best  and most economic care possible.

SQI has developed the following completely novel tests that address unmet needs in respiratory health, which have either been approved by or are awaiting approval from the Health Canada, U.S. FDA and EU EMEA regulatory bodies:

• • Transplantable Lungs- SQI has developed TORdx Donor Lung Test -a novel diagnostic test with over a 80% accuracy rate.  This test will enable surgeons to know if a donor lung will be highly likely to do well in the recipient’s body  and to increase the unmber of lungs that are transplanted (LUNG).  Currently over 80% of all donor lungs are discarded because there is no test to help decide between good and bad donor lungs. Lung Transplants cost over $1,000,00.00 USD and are one of the largest profit centers for any hospital.  There are no diagnostic tests available currently, a surgeon simply looks and feels the organ for any impurities. To determine if it will be accepted.

In a recent announcement by the Federal Government is going to shake up the transplant business and how transplant organs are managed.  The new system is completely in SQI’s testing favor.  See “Troubled U.S. Organ Transplant System Targeted for Overhaul”, Washington Post, 03/22/23.

• • Covid antibodies- SQI’s self-administered test, The EXACT ANTIBODY TEST is the ONLY QUANTITATIVE test that measures all 6 biomarkers.  The level of antibodies is critical.  It indicates the degree of immunity for vaccinated and unvaccinated individuals.  This test with over a 99% accuracy rate will also tell you if your immunity is from a vaccine/booster or whether you had Covid.  If the antibodies are below a certain threshold the individual now can take control of their own health.  They can decide whether they want to take a vaccine/booster, socially distance or wear a mask or not go out in public.  This test is covered by most major insurance companies.

The majority of the world population mistakenly believe that they have immunity from Covid 19 from having the disease or having been vaccinated.  As more gain an understanding that immunity from both wanes over time the demand for self-administered tests will increase substantially.   See “A look at how antibodies from a COVID-19 infection and vaccination wane over time”, PBS 10/19/21

• • Respiratory diseases diagnostics (RALI-Dx Triage Test) tests- SQI’s RALI-DX was developed to be utilized by hospitals. RALI-DX is a triage tool aid doctors to make better treatment decisions – send patient home or admit to hospital  or to treat with advanced respiratory  care measures.  This test is currently approved by Health Canada.  In Emergency Room Triage, patients with respiratory infections or trauma are  either sent home to rest and quarantine or are admitted to the hospital because the probability is high for the lungs to go into distress.  RALI-fast will be a test, similar to the “heart attack” point of care test by Biosite, that will help doctors send patients home or treat them aggressively – no test currently does this – and all in 15 minutes.   50% of all intensive care unit (ICU) admittances are related to a patient’s inability to breath normally.   Thus, since all hospitals are overcrowded, every hospital on the planet is in need of SQI’s RallyDX diagnostic system.    It can cost over $10,000 a day to keep a patient in the ICU — even more if they are intubated.  A 15 minute test by SQI could significantly reduce this cost and overcrowding in the ED.

For more about SQI’s testing products see “Four Diagnostic Products in the Pipeline at SQI”, March 3, 2023. 

The table below contains the status of the approvals for SQI’s three key product lines by the U.S., Canadian and European Union regulatory bodies.   All three provide significant upside for SQI and its shareholders.

SQI Tests underdevelopment

• • RALI-fast is a 15-minute version of the test that is nearing completion and can be used to triage ED patients and to monitor ICU patients. This is a massive market — there are over 25 million patient days in US ICUs alone.  The ICU Test has been trialed in a leading ICU with very positive feedback. 
  • Breathe — a simple, take-at-home test for lung transplant patients that monitor for post-operation infection which occurs in over 55% of lung transplant patients, and another for organ rejection.  (Comparable is CAREdx). This test where patient’s breath is collected replaces a complicated, expensive and risky in-hospital surgical biopsy procedure.  Breathe tests extend SQI’s product line into the highly valuable post-transplant monitoring markets like NASDAQ listed CAREdx (symbol: CDNA) which at 3/30/23 had a market cap of $489 million.

At first blush the debt on SQI’s Balance Sheet indicates substantial risk.  However, the risk for the Balance Sheet is mitigated since $9.7 million of the $16.2 million in total debt were loans that were provided by the company’s board members.  Most importantly, three SQI board members (Insiders) hold 75.4% of SQI common shares and 86.2% of its outstanding warrants: 

The three key directors, are among the most prominent members of Canada’s professional investor and investment banking community. 

• • Wilmot Matthews, former investment banker and Vice Chairman of BMO Nesbitt Burns. He and his wife donated $25 million to city of Toronto for a park. 
  • Clive Beddoe, founder of Hanover Holding and Investment Company, which manages approximately $200 million. Also founder of Westjet Airlines whose investment banker was Wilmot Matthews.  
  • Gerald Connor, founder of Cumberland Private Wealth Management, Inc., one of Canada’s largest investment management firms.

The paragraph below is an excerpt from the company’s March 28, 2023 “SQI to Focus on Development of Point of Care Products In Respiratory Health” announcement.

“As a part of SQI’s new strategy going forward, the Company has reduced its workforce from approximately 44 full-time employees to 20 full-time employees to focus on maintaining and developing the Company’s key capabilities of clinical and regulatory expertise, managing outsourced product development and outsourced manufacturing. The Company expects to reduce its payroll and cash burn by approximately 50% on a monthly basis. In connection with this evolution of the Company’s strategy, SQI intends to entertain offers from potential buyers for the Company’s now, non-core business that is based on lab-based instruments. The Company’s leadership will remain intact, including regulatory, clinical and finance roles.”

On 3/24/23, SQI announced that its insiders would be selling their shares to utilize the proceeds to exercise the money warrants that they hold.  See “SQI DIAGNOSTICS ANNOUNCES PROPOSED INSIDER SALES AND WARRANT EXERCISES TO FUND COMPANY”.  The announcement stated that insiders, who held warrants in SQI, would be selling shares at the “prevailing market price”.  The proceeds from the sales were to be utilized to exercise the warrants they hold at exercise prices of $0.12 to $0.21 per share.

Conclusion

SQI’s strategy of having insiders sell shares at below the warrant exercise prices and then to utilize the proceeds to exercise the warrants they hold at prices which are above the prices the shares were sold for is not new.  The strategy was successfully deployed by the three insiders to provide capital to SQI on three prior occasions.

• • SQI Diagnostics Inc. Announces Warrant Exercise by Insiders, July 3, 2020
  • SQI Diagnostics Announces $4 Million Funding via Warrant Exercise by Insiders, December 30, 2020
  • SQI Diagnostics Announces Proposed Insider Sales and Warrant Exercises to Fund Company, February 10, 2021

SQI has the best risk reward ratio of any stock that I have ever recommended throughout my 46 year career.  SQI is an extremely rare opportunity for two reasons:

• • Established or added to their legacies- SQI is a “change and improve the world” project.  
  • Protected or enhanced their reputations- A failure for any company in which they are board member would hurt their reputation.  
  • Increased their net worths by at least $174 million

To finance SQI, the three whales utilize a strategy of selling their common shares at prevailing market prices when it needs capital.  They then utilize the proceeds to exercise their warrants which have higher strike prices than the price their common shares were sold.  Thus, these whales provide an extremely rare opportunity for suckerfish or whalesuckers to have a free ride on their backs (purchase shares in open market near all-time low) to make approximately 20 times their investment. 

ShinyPennyStocks.com recommends that buy price limit orders at $0.05 be utilized to purchase SQIDF shares.  For future limit price order changes and updates on SQI Diagnostics subscribe to ShinyPennyStocks.com. 

Below are Money TV’s 3/31/23 interviews of SQI’s CEO, Andrew Morris and myself about SQI.  

SQI Diagnostics

Investview’s share price has been obliterated due to the company having a significant bitcoin mining operation.  The shares price is reflecting that the Investview is a bankruptcy candidate.   The chart below depicts the share prices of the five largest publicly traded bitcoin miners and bitcoin.   All of the minershave declined by at least 80% in 2022.  One of them, Core Scientific (Symbol:CORZ), recently declared bankruptcy.

For two reasons Investview is not a bankruptcy candidate:

1. Investview is not a pure bitcoin mining play. 76% of Investview’s revenue for its nine months ended 9/30/2022 were derived from subscription revenue.  Investview has more than 20,000 distributors who sell its educational trading products worldwide.  

2. Based on my analysis of Investview’s financials it is not a bankruptcy candidate. Since Investview has a tangible book value of $24.2 million the probability is very high that the it could be acquired at a premium to its current market cap (share price X shares outstanding) of $29.97 million.  INVU’s independent distributors who are in 120 countries is extremely valuable to any and every online broker or crypto broker.  The photo below was taken at an Investview distributor event in Egypt in 2021.  The photo depicts the wide range of demographics which include businessmen and young men & women.   

The tables below depict the comparisons of Investview’s key Financial Statement metrics for the quarter ended December 31, 2018 versus the nine months ended September 30, 2022.  2018 was chosen as the comparative year since December of 2018 was the last time that Investview shares could have been fetched at a penny or under.  

The key Income Statement metrics in the table below depict that Investview’s revenue increased by at least 106% for its nine months.  Even more importantly, its income from operations went from a negative $3.9 million to a positive $6.4 million.  Even though INVU’s revenue for the quarter had declined versus the 2021 quarter its annualized subscription revenue was $47.2 million at September 30, 2022. 

The table below depicts INVU’s key Balance Sheet metrics.   Current assets which grew by over 4,000% since 2018 and exceeded its Tangible Book Value at 9/30/2022.  Investview’s Current Ratio went from below 1.00 in 2018 to 2.2 in its recent quarter.  Investview’s shares outstanding only increased by a much slower pace of 19.32% from 2018 to 2022.  Most importantly, since INVU generated $7.3 million of operating cash flow for its nine months ended and had $26.6 million of cash September 30, 2022, there is no reason for the company to have to raise cash to dilute its shareholders.

Due to its shares having declined substantially since 2021, Investview and its shares are a tax loss sale candidate. This means that the share price will likely go to a new low for the year this week.  Many who purchased the shares at much higher prices and have held them for more than a year will sell them to create a tax loss that they can use to offset capital gains taken during the year.  The chart below depicts the Investview’s low since 2018 occurred in December of 2018. The lows were because INVU shares were also a tax loss candidate in December 2018.   

Investview shares could easily multiply by several times by the end of the first quarter of 2023 when compared to their current price.  The price of a bitcoin which is also a tax loss sale candidate could easily increase by 50% to 100% from their 2022 low.  The chart below depicts Bitcoin’s price from December 2020 to December 2022.  The green shaded area in the chart depicts the sideways pattern for the price of a Bitcoin from November 6, 2022 through December 25, 2022.  The chart indicates that the crypto currency has already, or is in the process of bottoming.

Upon Bitcoin bottoming and its price increasing the revenue and profits of all of the crypto miners will increase.  This will result in the share prices of the miners bouncing.  A good rule of thumb is the price of the shares of those companies that have declined by at least 80%, and which have not gone bankrupt, will bounce to within 50% of their trailing 12-month highs.  Since the highest price of INVU shares for 2022 was 0.1065 the share price could easily bounce back to $0.5 in 2023 for a gain of approximately 400 percent from the current penny per share price.    

Investview’s share price will be under severe pressure until the close of 12/30/22.  To obtain the lowest possible prices throughout this week, I recommend that you subscribe to a 90-day complementary trial to ShinyPennyStocks.com.  This will enable you to receive text message alerts, which will be sent out to all subscribers throughout the week.  The messages will contain the price buy limits and the percentage of available funds to be utilized for each of the price limits. 

ShinyPennyStocks.com’s goal is to assist its subscribers to accumulate their shares at an average price that could potentially be at or below the closing price of INVU shares on 12/30/2022.  The best way to have a cost basis which is lower than the close of 12/30/22 is by averaging in.  ShinyPennyStocks.com will also be making additional average- in recommendations on the other companies it is closely following via text messages throughout the week. If you are already a ShinyPennyStocks.com subscriber you need to re-subscribe to the Complementary 90 day trial.  Otherwise, you will not get the text messages. 

Finally, I have forecasted a 77.36% decline for the S&P 500 and for investors to adopt a defensive investing posture.  One of the asset classes that performs well during substantial blue-chip declines is penny stocks.   For more about my forecast and my defensive Return of Capital versus a Return on Capital strategy I am recommending the article entitled “Markowski’s Latest, “S&P 500 to Decline by 77.36 Percent from January 2022 Peak” ⎯ Bottom at 1090.90” by Paul Lengemann.   

Kings Entertainment Group Inc. (JKPT) is an international online service provider for lottery, casino, and sportsbook gambling and parent company of global online gaming innovators LottoKings and WinTrillions. It started trading 01/24/2022 on the Canadian (CN) stock exchange.

Strategically positioning as the industry is expected to more than doubles to USD $127.3 billion by 2027 from 2021’s USD $53 billion, according to a new report by Grand View Research, Inc and FORBES.

Highlights from JKPT operations in February 2022, include new registrations, growth in depositing customers and continued casino growth. It’s 2021 NET REVENUE: USD $5.9 MILLION.

The recent campaigns were successful in boosting registrations by 136 percent over January, despite the three day shorter month, with 15,449 customer sign-ups achieved in February. One of Kings Entertainment’s flagship brands, LottoKings, achieved a 30 percent increase in revenue in February over the previous month.

It’s goal of increasing casino revenue in February was successful with live casino  increasing active players by 12 percent. Revenue for casino operations jumped by 36 percent in February to $118,491, as compared to the first 28 days of January.

“The success of these marketing campaigns will be instrumental to our revenue strategy this fiscal year,” said Steve Budin, CEO of Kings Entertainment. “While the lack of significant jackpots in February dampened overall demand for lottery, the increase in both active casino players and casino revenue is a very positive signal that our strategy of transitioning our strong lottery base to the casino vertical is working.”

Online Gambling Market Size Worth $127.3 Billion By 2027 

Online Gambling Market Growth & Trends – https://www.grandviewresearch.com

U.S. Gambling Revenue Hit Record $53 Billion In 2021 – Forbes

Investview’s SEC filing on (3/31/22) was extremely significant.  Its shares (symbol:INVU) should be aggressively purchased at or under ShinyPennyStocks.com’s $0.10 buy limit price.   The shares could soon pierce through the $0.10 barrier based on what was revealed in the filing and/or upon my new report that is currently in progress and which will be published next week.  My report will provide the rationale for why the share price could reach $4.03 by 2027.   See 3/22/22 “Report in Support of $4.03 INVU share price, to soon be available”.

The SEC filing disclosed that Investview had delayed the filing of its Financial report for its fiscal year ended 12/31/21, which was due on 3/31/22.  The delay was to provide its newly appointed CEO, extra time to thoroughly review its financials.  In addition, Investview disclosed that it had:

• “Substantially increased the scale and scope of its operations since the previous fiscal year ended 3/31/22. It is anticipated that there will be a significant increase in revenue and earnings from the previous fiscal year (the twelve months ended March 31, 2021) to the current transition period (the nine months ended December 31, 2021)”

Significance:  A company’s revenue and earnings for a stub period (9 months) being substantially higher than revenue and earnings for a full period (12 months) is extremely rare. For INVU, this is especially a significant development.  It indicates that kerosene has been poured on INVU’s already raging growth fire.

• Changed its fiscal year from March 31 to December 31.

Significance:  From my experience a rationale for a company to change its fiscal year to a calendar year end (December 31st) is to meet the requirement for a listing on a national securities exchange.   My soon to be published report will elaborate on the biggest reason for INVU shares continue to underperform even though the company’s FREE CASH FLOW, Revenue and EPS growth has continued to break record after record.  It is because the shares are not listed on NASDAQ or the NYSE.  Upon the shares becoming listed my unadjusted share price target for 2022 is $0.30 based on my free cash flow yield metrics.  For more about my Free Cash flow Yield valuation metrics read 11/12/21, “Investview, Ridiculously Undervalued! Article”.

“Unadjusted” is included since it’s likely that INVU will be required to reverse split its shares for them to become listed.  The table below depicts that based on a pre-split or a post-split price 100,000 INVU shares @ 4/2/22 are projected to be valued $30,000.

As soon as Investview announces the split and the split ratio, the $0.30 target price for 2022 will be adjusted accordingly.  Subscribe to ShinyPennyStocks.com to receive alerts about the reports which are published by the website. 

I highly recommend that that INVU shares have a 5% of a portfolio weighting.   It’s especially since I have predicted that the Secular Bull market which began in March of 2009, ended on January 4, 2022.  See my 03/20/22  “Due to inflation’s effect on PE, S&P 500 to decline 45%” article.  It explains that a new secular bear, the first since 2000-2009, began at the early January all-time  high.  Based on the prior secular bears, which are depicted in the table below, the S&P 500 will decline by a minimum of 47% and will have a minimum duration of 8 years.   The asset class which produces all of the long-term capital gains during a secular bear are small companies and those which have low stock prices.

The educational videos below about secular bear markets are highly recommended.  “Proven Secular Bear investing strategies” explains why low-priced shares and shares of small companies are best to own during the new secular bear market which has begun.   “Why the worst performing stocks during a secular bear were always the best performers of the prior secular bull” explains why high priced and blue-chip shares decline during secular bears.